HAS acquires Cerbios-Pharma SA
LUGANO, Switzerland • March 31th, 2025 • Today we are proud to announce that Cerbios-Pharma SA, Switzerland and HAS Advanced Synthesis SA, Switzerland (HAS), are joining their forces. Download the Press Release
Cerbios-Pharma S.A. Boosts Production Capabilities for HPAPIs and ADCs
LUGANO, Switzerland • February 28th, 2025 • Cerbios-Pharma is proud to announce the opening of a new expansion area at the Lugano site for clinical and commercial manufacturing of Highly Potent Active Pharmaceutical Ingredients (HPAPIs), including cytotoxic linker payloads for antibody-drug conjugates (ADCs). The inauguration was conducted in the presence of Christian Suà, CEO of…
Cerbios-Pharma Commits to Sustainability with New Solar Panel Installation in Lugano
LUGANO, Switzerland • April 8th, 2024 • Cerbios-Pharma SA is proud to announce the completion of a photovoltaic power plant at its Lugano site. This new milestone marks a significant step forward in the Company’s commitment to environmental protection and sustainability, further to last year’s implementation of a new solvent collection and separation process which…
HPAPI and ADC payload manufacturing capacity expansion
LUGANO, Switzerland • May 10th, 2023 • During our long standing 45 years history in the pharmaceutical industry, as Cerbios-Pharma, we have always invested in expanding our capabilities and in the last years more and more resources were addressed to support our customers with innovative CDMO services for HPAPIs and ADCs. Today, we are pleased…
SF68® IBSoft (under development)
Indications: indicated for the dietary management of colonopathies with altered trophism of the intestinal mucosa
Regulatory status: to be defined
SF68® Slipido
Indications: for maintenance of normal blood levels of cholesterol and normal metabolism of homocysteine
Regulatory status: Food Supplement (EU & Switzerland)
SF68® Skin Active
Indications: for maintenance of normal skin
Regulatory status: Food Supplement (EU & Switzerland)
New additional R&D laboratory unit
LUGANO, Switzerland • May 31th, 2022 • Cerbios-Pharma SA announces the opening, at its Lugano site, of an additional R&D laboratory unit equipped with state-of-the-art technologies. This new space will host an area for the development activities related to Highly Potent Molecules and a separate section for the analytical support of CDMO projects. These laboratories, designed…
Pharma Tech Outlook – Top 10 EU CMO’s 2022 – Cerbios Cover Story (April 2022)
LUGANO, Switzerland • April 13th, 2022 • We are proud to announce that Pharma Tech Outlook named Cerbios as Top CMO for 2022. A panel of experts and members of Pharma Tech Outlook’s editorial board defined the pool of companies noteworthy in 2022 and our innovating end-to-end services were evaluated as worth to gain the magazine cover story…
Cerbios announces the near finalization of a new cGMP unit for cytotoxic, a further step towards HPAPIs and ADCs market needs
LUGANO, Switzerland • April 13th, 2022 • Swiss based Cerbios-Pharma SA, specialized in the development and manufacturing of chemical and biotechnological APIs, is officially announcing the near finalization of the structure for its new manufacturing building dedicated to High Potency Active Ingredients (HPAPI), which will host 2 additional cGMP production lines for Cytotoxic molecules and additional…
